SenzaGen (SENZA) Q3 2025 earnings summary

Executive summary

• Achieved break-even in Q3 2025, with net sales up 15% year-over-year to SEK 15.2 million and positive performance in the GARD® core business.

• Added 10 new customers, including 5 large global companies, and maintained high customer loyalty with 85% of sales from existing clients.

• Growth driven by focused sales efforts, strong cost discipline, and robust demand, especially in the US market.

• Strategic priorities focus on scaling the business, enhancing efficiency, and investing for future growth through both organic and acquisition-driven initiatives.

• VitroScreen showed a positive trend after management changes, with sales up 15% and declining costs.

Financial highlights

• Q3 2025 revenue reached SEK 15.2M, up 15% year-over-year (18% FX-adjusted).

• GARD® sales were SEK 10.5M, up 12% quarter-over-quarter and year-over-year.

• Gross margin stable at 66%, with a slight product mix effect and impact from lower-margin third-party tests.

• EBITDA at break-even, reflecting strong cost discipline.

• Cash and cash equivalents at SEK 29.3M at quarter-end.

Outlook and guidance

• High industry engagement expected to boost future sales following OECD TG 497 approval.

• Regulatory initiatives progressing, with OECD and ISO standard inclusions targeted for 2027, anticipated to significantly increase demand.

• R&D pipeline and test portfolio expansion expected to drive future revenue growth.

• Continued emphasis on efficiency, process optimization, and cost control to improve profitability and cash flow.

• Focus remains on scaling up business, strengthening operational efficiency, and investing in growth initiatives.